Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?

IF 3.8 3区医学 Q2 VIROLOGY Viruses-Basel Pub Date : 2024-10-31 DOI:10.3390/v16111710

Giovana Paula Angelice, Pedro Henrique Roque, Gabriel Valente, Krishna Galvão, Livia Melo Villar, Vinicius Motta Mello, Francisco C A Mello, Bárbara Vieira Lago

{"title":"Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?","authors":"Giovana Paula Angelice, Pedro Henrique Roque, Gabriel Valente, Krishna Galvão, Livia Melo Villar, Vinicius Motta Mello, Francisco C A Mello, Bárbara Vieira Lago","doi":"10.3390/v16111710","DOIUrl":null,"url":null,"abstract":"Background: Despite an existing safe and effective vaccine for hepatitis B virus (HBV), it is still a major public health concern. Nowadays, several drugs are used to treat chronic hepatitis B; however, full healing remains controversial. The viral covalently closed circular DNA (cccDNA) formed by HBV forms a major challenge in its treatment, as does the ability of HBV to integrate itself into the host genome, which enables infection reactivation. Interfering RNA (RNAi) is a gene-silencing post-transcriptional mechanism which forms as a promising alternative to treat chronic hepatitis B. The aim of the present review is to assess the evolution of hepatitis B treatment approaches based on using RNA interference.Methods: Data published between 2016 and 2023 in scientific databases (PubMed, PMC, LILACS, and Bireme) were assessed.Results: In total, 76,949 articles were initially identified and quality-checked, and 226 eligible reports were analyzed in depth. The main genomic targets, delivery systems, and major HBV therapy innovations are discussed in this review. This review reinforces the therapeutic potential of RNAi and identifies the need for conducting further studies to fill the remaining gaps between bench and clinical practice.","PeriodicalId":49328,"journal":{"name":"Viruses-Basel","volume":"16 11","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11598949/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Viruses-Basel","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/v16111710","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Despite an existing safe and effective vaccine for hepatitis B virus (HBV), it is still a major public health concern. Nowadays, several drugs are used to treat chronic hepatitis B; however, full healing remains controversial. The viral covalently closed circular DNA (cccDNA) formed by HBV forms a major challenge in its treatment, as does the ability of HBV to integrate itself into the host genome, which enables infection reactivation. Interfering RNA (RNAi) is a gene-silencing post-transcriptional mechanism which forms as a promising alternative to treat chronic hepatitis B. The aim of the present review is to assess the evolution of hepatitis B treatment approaches based on using RNA interference.

Methods: Data published between 2016 and 2023 in scientific databases (PubMed, PMC, LILACS, and Bireme) were assessed.

Results: In total, 76,949 articles were initially identified and quality-checked, and 226 eligible reports were analyzed in depth. The main genomic targets, delivery systems, and major HBV therapy innovations are discussed in this review. This review reinforces the therapeutic potential of RNAi and identifies the need for conducting further studies to fill the remaining gaps between bench and clinical practice.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估干扰 RNA 治疗乙型肝炎的疗效：有希望吗？

背景：尽管目前已有安全有效的乙型肝炎病毒（HBV）疫苗，但它仍然是一个重大的公共卫生问题。如今，有多种药物可用于治疗慢性乙型肝炎，但能否完全治愈仍存在争议。HBV 形成的病毒共价闭合环状 DNA（cccDNA），以及 HBV 将自身整合到宿主基因组中的能力，使感染重新活化，都对治疗构成了重大挑战。干扰 RNA（RNAi）是一种基因沉默转录后机制，是治疗慢性乙型肝炎的一种有前途的替代方法。本综述旨在评估基于使用 RNA 干扰的乙型肝炎治疗方法的演变情况：方法：对科学数据库（PubMed、PMC、LILACS 和 Bireme）中 2016 年至 2023 年间发表的数据进行评估：共初步识别并质量检查了 76949 篇文章，对符合条件的 226 篇报告进行了深入分析。本综述讨论了主要的基因组靶点、给药系统和主要的 HBV 治疗创新。这篇综述加强了 RNAi 的治疗潜力，并明确了开展进一步研究的必要性，以填补临床实践与研究之间的空白。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Viruses-Basel VIROLOGY-

CiteScore

7.30

自引率

12.80%

发文量

2445

审稿时长

1 months

期刊介绍： Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the ''News and Views'' section. Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.